Peptide injection-site reactions: redness, lumps and when it's an infection

What is normal

Any injection under the skin can cause a small local reaction. Approved peptide medicines document this in their labels. The label for EGRIFTA WR (tesamorelin) reports injection-site reactions, including redness, itching, pain, irritation and bruising, in 25% of treated patients against 14% on placebo during the first 26 weeks of trials, and advises rotating sites around the abdomen to reduce them (drug label, trial data) ¹. The SKYTROFA (lonapegsomatropin) label tells users to rotate between and within regions to reduce the risk of lipoatrophy, a loss of fat under the skin (drug label) ².

So a small red patch, a little itching or tenderness, or a bruise that fades within a day or two is common and usually harmless. Note that even placebo injections caused reactions in one in seven people in those trials ¹: the needle and the volume of fluid do part of it, whatever is in the syringe.

Lumps from injecting the same spot

Repeated injections into one area can change the fat under the skin. The best-studied example is lipohypertrophy in people who inject insulin, a thickened, rubbery swelling at overused sites. A 2021 meta-analysis of 45 studies and 26,865 people found it in about 42% of insulin users (meta-analysis) ³. A 2024 meta-analysis of risk factors found the strongest contributor was incorrect site rotation (odds ratio 8.85), followed by needle reuse (3.20) and more than five years of injections (meta-analysis) ⁴. A 2026 international consensus adds that it can make absorption unpredictable and push insulin needs up by as much as a quarter (expert consensus) ⁵.

Insulin is a peptide hormone, but these numbers come from insulin users, not from people injecting research peptides, so they show the mechanism rather than the rate for any particular product. The lesson transfers: rotate sites, do not keep injecting into a lump, and do not reuse needles.

When it is an infection

Bacteria from the skin, the needle, the vial or the environment can cause an infection at the site. The general warning signs are redness that spreads rather than fades, warmth, swelling, increasing pain after the first day, pus, red streaks, or fever and feeling unwell. Those need a clinician, promptly, and urgently if the redness spreads quickly or there is fever. Do not try to drain a lump yourself.

A second kind of infection is slower and easier to miss. Nontuberculous mycobacteria are environmental organisms, found in water and soil, that can enter the skin through an injection or procedure; a 2013 review lists skin and soft-tissue infection among their common forms outside the lungs and notes outbreaks caused by contaminated injected solutions or medications and poorly disinfected equipment (review) ⁶. Unlike tuberculosis, they are not known to pass from person to person, and only about one in ten of their infections occurs outside the lungs, which is one reason clinicians may not think of them at first ⁶. They tend to cause firm lumps, abscesses or sores that develop over weeks and do not respond to the antibiotics usually used for skin infections, which is why it matters to tell a clinician exactly what was injected and where it came from.

What the outbreaks teach

Documented outbreaks show how ordinary shortcuts cause these infections. At a rural clinic in China in 2006, 35 people developed buttock abscesses after intramuscular injections; every case had received drugs mixed with saline from 100 mL multiple-dose bottles, investigators found a needle left in the bottles' rubber stoppers and reused, and Mycobacterium abscessus grew from abscesses and from the clinic's water supply. The investigators noted that 14% of the village's registered residents had received intramuscular drugs over three months, often for minor illnesses, a reminder of how many people one contaminated bottle can reach (outbreak investigation) ⁷. In France, severe infections after mesotherapy, injections of mixtures into the skin for cosmetic purposes, were linked to a multiple-injection device cleaned with tap water (outbreak investigation) ⁸. In Spain in 2009, healthy women developed abscesses from M. abscessus after mesotherapy at an aesthetic clinic (outbreak investigation) ⁹.

The common thread is contamination of something used more than once: a bottle, a needle, a device. Home injection of peptides from multi-use vials, reconstituted with water and drawn repeatedly, has the same structure.

Vials, water and what sterile means

CDC's injection-safety guidance describes multi-dose vials as containers labelled as such by the manufacturer that usually contain a preservative to help limit bacterial growth; its training material adds that the preservative has no effect on viruses ^{10 11}. CDC advises that an opened or needle-punctured multi-dose vial be dated and discarded within 28 days unless the manufacturer gives a different date, never beyond the original expiry, and that any vial whose sterility is in question be discarded ¹⁰. Our bacteriostatic water guide explains why the choice of diluent matters.

The bigger issue for research peptides is that they are not made as sterile medicines for people. An approved injectable is manufactured and tested for sterility and endotoxins; a powder labelled for research use carries no such assurance, so careful technique at home cannot fix contamination that came in the vial. Our guide to what research use only means covers that gap.

Where approved peptides are injected

The labels of approved injectable peptides are a practical guide to sites. Wegovy and Zepbound are injected under the skin of the abdomen, thigh or upper arm, with Zepbound's label specifying the back of the upper arm when another person gives the injection ¹². EGRIFTA WR is injected into the abdomen, rotating sites around it ¹. SKYTROFA, a weekly growth hormone, goes into the abdomen, buttock or thigh, rotating between and within those regions ². Every one of these labels builds rotation into the instructions.

A simple way to rotate is to divide each area into sections and move around them in order, keeping a short note of the last site used, and to leave a gap of a couple of centimetres from the previous injection. Avoid the navel, scars, moles, stretch marks, bruises and any lump. If a site stays sore, skip it until it has settled. None of this needs special equipment, and in insulin users it is the single habit most strongly linked with avoiding fatty lumps ⁴.

Basic precautions

• Use a new sterile needle and syringe for every injection, and never put a used needle back into a vial; the saline-bottle outbreak above began with a reused needle left in a stopper ⁷.
• Clean the vial stopper and the skin before injecting, and let the skin dry.
• Rotate injection sites within and between areas, and avoid lumps, bruises and broken skin ^{4 2}.
• Date opened vials and discard them as their makers direct, or within 28 days where no date is given; discard anything cloudy, discoloured or doubtful ¹⁰.
• Do not share vials, needles or pens with anyone.

Lumps that do not go away

Some lumps are neither a simple reaction nor an obvious infection: a firm nodule that persists for weeks or months. Possible causes include a slow mycobacterial infection ⁶, a granuloma, the body walling off material it cannot clear, or changes in the fat under the skin such as lipohypertrophy or lipoatrophy ^{3 2}. These are hard to tell apart without an examination, and sometimes a culture or biopsy. A persistent lump after injecting an unapproved product is a reason to see a clinician, not a reason to keep injecting nearby.

When to see a clinician

Seek care promptly for redness that spreads or keeps growing after the first day, warmth and swelling with increasing pain, pus or a lump that feels fluid-filled, red streaks, fever, chills or feeling unwell, or a sore that will not heal. Seek care for any lump that persists beyond a couple of weeks or keeps coming back. Seek emergency care for signs of a severe allergic reaction, such as swelling of the face or throat, trouble breathing or a widespread rash, after any injection.

Bring the product with you, or its name, batch and where it was bought, along with the date you first noticed the change and the dates of recent injections. That information changes what tests a clinician orders and which antibiotics will work.

The bottom line

Mild redness or a bruise is common after peptide injections, approved or not, and rotating sites prevents most lumps from repeated use. Infections are less common but more serious, and the slow ones from contaminated vials or equipment can surface weeks later and resist ordinary antibiotics. With research products that were never made as sterile medicines, the safest technique still cannot guarantee a sterile injection, so any worsening, spreading or persistent change deserves a clinician's look.

Frequently asked questions

Is a red bump after a peptide injection normal?

A small red, itchy or tender patch that fades within a day or two is common. Approved injectable peptides report such reactions, and even placebo injections cause some.

Why do I have a lump where I inject?

Often from injecting the same spot repeatedly, which can thicken the fat under the skin. In insulin users, poor site rotation and needle reuse are the strongest risk factors. A lump that is hot, painful or growing needs a clinician.

How do I know if my injection site is infected?

Spreading redness, warmth, swelling, increasing pain, pus, red streaks or fever suggest infection and need prompt care. Slow infections can appear as firm lumps weeks later.

Can contaminated vials cause infections?

Yes. Outbreaks of slow mycobacterial infections have been traced to contaminated multi-dose saline bottles and poorly cleaned injection equipment.

Should I keep injecting if a site is sore?

Rotate to a different area and watch the sore site. Stop and see a clinician if it worsens, spreads or persists.

Related on Grey Peptides

• Bacteriostatic water guide
• What research use only means
• Tesamorelin

Sources

1. Theratechnologies. EGRIFTA WR (tesamorelin) US prescribing information, sections 2.1 and 5.6 (Injection Site Reactions). DailyMed version 2, effective July 29, 2026; read October 1, 2026.
2. Ascendis Pharma. SKYTROFA (lonapegsomatropin-tcgd) US prescribing information, section 2 (Dosage and Administration: rotation of injection sites). DailyMed version 13, effective July 23, 2026; read October 1, 2026.
3. Wang, K., et al. (2021). A meta-analysis and meta-regression on the prevalence of lipohypertrophy in diabetic patients on insulin therapy. Therapie, 76(6), 617-628. PMID: 33958198
4. Mader, J. K., et al. (2026). Risk factors for Lipohypertrophy in People With Insulin-Treated Diabetes: A Systematic Meta-Analysis. J Diabetes Sci Technol, 20(4), 1342-1352. PMID: 40109173
5. Guo, L., et al. (2026). Consensus Recommendations on Lipohypertrophy: Insights From an International Panel of Experts. Diabetes Res Clin Pract, 239, 113401. PMID: 42398590
6. Kasperbauer, S., et al. (2013). Management of extrapulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med, 34(1), 143-50. PMID: 23460014
7. Yuan, J., et al. (2009). Mycobacterium abscessus post-injection abscesses from extrinsic contamination of multiple-dose bottles of normal saline in a rural clinic. Int J Infect Dis, 13(5), 537-42. PMID: 19269204
8. Carbonne, A., et al. (2009). Outbreak of nontuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. J Clin Microbiol, 47(6), 1961-4. PMID: 19386853
9. Galmés-Truyols, A., et al. (2011). An outbreak of cutaneous infection due to Mycobacterium abscessus associated to mesotherapy. Enferm Infecc Microbiol Clin, 29(7), 510-4. PMID: 21684045
10. Centers for Disease Control and Prevention. Preventing Unsafe Injection Practices (Injection Safety: clinical safety). Read October 2, 2026. CDC
11. Centers for Disease Control and Prevention. Safe Injection Practices, Module 6 (dental infection control training script). Read October 2, 2026. CDC
12. Novo Nordisk. WEGOVY (semaglutide) and Eli Lilly. ZEPBOUND (tirzepatide) US prescribing information, Dosage and Administration (injection sites). DailyMed versions 19 (effective June 18, 2026) and 40 (effective August 28, 2026); read October 1, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.